Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT05739435
Active, not recruiting Phase 2

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

NCT05739435 · tracked via the Priya Life Science USA tracker
Sponsor
Alumis Inc
Phase
Phase 2
Started
2023-01-17
Last updated
2026-07-28

Condition(s) studied

Plaque Psoriasis

Investigational drug(s) / intervention(s)

envudeucitinib →

envudeucitinib: Oral tablet

Study summary

This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Must have completed a prior ESK-001 study * Men and Women must use highly effective methods of contraception for the entirety of the study Exclusion Criteria: * Pregnancy * Received a prohibited concomitant medication

Primary outcome measure(s)

  • To assess the safety and tolerability of long-term ESK-001 treatment — Approximately 3 years
    Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

Trial sites (38)

FacilityCityRegionStatus
Investigator Site # 1029 Birmingham Alabama
Investigator Site #1001 Phoenix Arizona
Investigator Site # 1023 Rogers Arkansas
Investigator Site #1021 Encinitas California
Investigator Site #1018 Los Angeles California
Investigator Site #1007 Santa Monica California
Investigator Site #1002 Sherman Oaks California
Investigator site # 1030 Fort Lauderdale Florida
Investigator Site #1025 Hialeah Florida
Investigator site # 1028 Miami Florida
Investigator Site # 1013 Tampa Florida
Investigator Site #1035 Macon Georgia
Investigator Site #1043 Sandy Springs Georgia
Investigator Site #1005 Rolling Meadows Illinois
Investigator Site # 1011 Columbus Indiana
Investigator Site #1027 South Bend Indiana
Investigator SIte#1036 Overland Park Kansas
Investigator Site #1017 Owensboro Kentucky
Investigator Site #1026 Rockville Maryland
Investigator Site #1010 Clarkston Michigan
Investigator Site #1031 New Brighton Minnesota
Investigator Site #1033 Norman Oklahoma
Investigator Site #1019 Portland Oregon
Investigator Site #1022 Philadelphia Pennsylvania
Investigator Site # 1012 Rapid City South Dakota
Investigator Site #1015 Houston Texas
Investigator Site # 1006 San Antonio Texas
Investigator Site # 1041 South Jordan Utah
Investigator Site #2001 Edmonton Alberta
Investigator Site # 2008 Surrey British Columbia
Investigator Site #2003 Winnipeg Manitoba
Investigator Site #2006 London Ontario
Investigator Site # 2004 Mississauga Ontario
Investigator Site # 2007 North Bay Ontario
Investigator Site #2005 Oakville Ontario
Investigator Site #2009 Toronto Ontario
Investigator Site # 2002 Waterloo Ontario
Investigator Site # 2010 Québec Quebec

More Alumis Inc trials in the USA

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis Active, not recruiting

Other trials for the same condition

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis Recruiting
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis Recruiting
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05739435 on ClinicalTrials.gov ↗ ← All trials in the USA